The case for treatment of monogenic SRNS with calcineurin inhibitors.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37085258.
- Also identified by DOI 10.1016/j.kint.2023.02.017 and PMC identifier 10434727.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Currently, no evidence-based guidelines exist for treatment of children with monogenic steroid-resistant nephrotic syndrome. A retrospective study on 141 patients from Malakasioti et al. revealed that 27.6% responded to calcineurin inhibitor (CNI) treatment, and 75% of responders maintained stable kidney function. Virtually all CNI nonresponders developed progressive loss of kidney function. This study emphasized roles for CNIs in patients with monogenic steroid-resistant nephrotic syndrome, and the need for future studies to identify CNI response biomarkers.
Medical subject headings
- Calcineurin Inhibitors
- Nephrotic Syndrome